Literature DB >> 20353832

Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease.

Nathan Cantoni1, Hans H Hirsch, Nina Khanna, Sabine Gerull, Andreas Buser, Christoph Bucher, Jörg Halter, Dominik Heim, André Tichelli, Alois Gratwohl, Martin Stern.   

Abstract

Cytomegalovirus (CMV) infection and graft-versus-host disease (GVHD) are important complications after allogeneic hematopoietic stem cell transplantation (HSCT) with a clear link. Multiple studies show that GVHD and its treatment put patients at risk for CMV replication. Data on CMV replication as a cause of GVHD, in contrast, are controversial. We analyzed the reciprocal association of CMV replication with acute GVHD (aGVHD) in 515 patients treated with allogeneic HSCT between 1993 and 2008. Cumulative incidences at day 100 were 17% for CMV replication, 68% for aGVHD grade I-IV, and 48% for GVHD grade II-IV. Multivariate time-dependent analyses revealed that the presence of GVHD increased the risk of CMV replication in a dose-dependent manner: hazard ratio (HR) for CMV replication for patients with aGVHD grade I was 1.35 (95% confidence interval [CI] 0.82-2.21); HR for patients with aGVHD grade II-IV was 1.61 (95% CI 1.11-2.36, P-value for trend = .01). During phases of CMV replication, patients were at increased risk of developing aGVHD (HR 2.18, 95% CI 1.30-3.65, P < .01). These data confirm that GVHD and its therapy can induce CMV replication. They further demonstrate the reciprocal novel finding that patients are at significantly increased risk of developing aGVHD during CMV replication. Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20353832     DOI: 10.1016/j.bbmt.2010.03.020

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  69 in total

1.  Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study.

Authors:  Yamin Tan; Haowen Xiao; Depei Wu; Yi Luo; Jianping Lan; Qifa Liu; Kang Yu; Jimin Shi; Jingsong He; Weiyan Zheng; Xiaoyu Lai; Yuanyuan Zhu; Kaili Du; Yishan Ye; Yanmin Zhao; Gaofeng Zheng; Yongxian Hu; Xiaoyan Han; Yanlong Zheng; Guoqing Wei; Zhen Cai; He Huang
Journal:  Oncoimmunology       Date:  2017-01-06       Impact factor: 8.110

2.  First-Onset Herpesviral Infection and Lung Injury in Allogeneic Hematopoietic Cell Transplantation.

Authors:  Xiaofeng Zhou; David N O'Dwyer; Meng Xia; Holly K Miller; Paul R Chan; Kelsey Trulik; Mathew M Chadwick; Timothy C Hoffman; Camille Bulte; Kevin Sekerak; Carol A Wilke; Swapneel J Patel; Wayne M Yokoyama; Susan Murray; Gregory A Yanik; Bethany B Moore
Journal:  Am J Respir Crit Care Med       Date:  2019-07-01       Impact factor: 21.405

3.  Dynamics of Torque Teno virus viremia could predict risk of complications after allogeneic hematopoietic stem cell transplantation.

Authors:  Ramona Gilles; Marco Herling; Udo Holtick; Eva Heger; Sabine Awerkiew; Irina Fish; Konstantin Höller; Saleta Sierra; Elena Knops; Rolf Kaiser; Christof Scheid; Veronica Di Cristanziano
Journal:  Med Microbiol Immunol       Date:  2017-07-12       Impact factor: 3.402

4.  Not just leukemia: CMV may protect against lymphoma recurrence after allogeneic transplant.

Authors:  Jonathan U Peled; Robert R Jenq
Journal:  Leuk Lymphoma       Date:  2016-10-12

5.  Acute graft-versus-host disease: more than just alloreactivity.

Authors:  Richard Champlin
Journal:  Blood       Date:  2014-07-10       Impact factor: 22.113

6.  Genetic T-cell receptor diversity at 1 year following allogeneic hematopoietic stem cell transplantation.

Authors:  Stéphane Buhler; Florence Bettens; Carole Dantin; Sylvie Ferrari-Lacraz; Marc Ansari; Anne-Claire Mamez; Stavroula Masouridi-Levrat; Yves Chalandon; Jean Villard
Journal:  Leukemia       Date:  2019-11-26       Impact factor: 11.528

7.  Invasive fungal disease is associated with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplant: a single center, retrospective study.

Authors:  Hua Jin; Zhiping Fan; Fen Huang; Yanyan Chai; Li Xuan; Ren Lin; Na Xu; Jieyu Ye; Jing Sun; Qifa Liu
Journal:  Infection       Date:  2019-02-07       Impact factor: 3.553

8.  How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation.

Authors:  Hermann Einsele; Per Ljungman; Michael Boeckh
Journal:  Blood       Date:  2020-05-07       Impact factor: 22.113

9.  Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status.

Authors:  Raphael Carapito; Ismail Aouadi; Angélique Pichot; Perrine Spinnhirny; Aurore Morlon; Irina Kotova; Cécile Macquin; Véronique Rolli; Anne Cesbron; Katia Gagne; Machteld Oudshoorn; Bronno van der Holt; Myriam Labalette; Eric Spierings; Christophe Picard; Pascale Loiseau; Ryad Tamouza; Antoine Toubert; Anne Parissiadis; Valérie Dubois; Catherine Paillard; Myriam Maumy-Bertrand; Frédéric Bertrand; Peter A von dem Borne; Jürgen H E Kuball; Mauricette Michallet; Bruno Lioure; Régis Peffault de Latour; Didier Blaise; Jan J Cornelissen; Ibrahim Yakoub-Agha; Frans Claas; Philippe Moreau; Dominique Charron; Mohamad Mohty; Yasuo Morishima; Gérard Socié; Seiamak Bahram
Journal:  Bone Marrow Transplant       Date:  2020-04-14       Impact factor: 5.483

10.  Comprehensive Prognostication in Critically Ill Pediatric Hematopoietic Cell Transplant Patients: Results from Merging the Center for International Blood and Marrow Transplant Research (CIBMTR) and Virtual Pediatric Systems (VPS) Registries.

Authors:  Matt S Zinter; Brent R Logan; Caitrin Fretham; Anil Sapru; Allistair Abraham; Mahmoud D Aljurf; Staci D Arnold; Andrew Artz; Jeffery J Auletta; Saurabh Chhabra; Edward Copelan; Christine Duncan; Robert P Gale; Eva Guinan; Peiman Hematti; Amy K Keating; David I Marks; Richard Olsson; Bipin N Savani; Celalettin Ustun; Kirsten M Williams; Marcelo C Pasquini; Christopher C Dvorak
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-26       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.